Recombinant DNA technology Market By Product Type (Medical (Human Protein, Therapeutic Agent, and Vaccine) and Non-medical (Specialty Chemical, Biotech Crops, and Others)), By Component Type (Expression System (Mammalian, Bacteria, Yeast, Baculovirus/Insect, and Others) and Cloning Vector), By Application Type (Agriculture and Pharmaceuticals (Human, Animal, Environment, and Others)), By End User (Pharmaceutical Companies, Research Institutes, and Others), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI25619 | Publish Date: April 2024 | No. of Pages: 180

Global Recombinant DNA Technology Market Companies

  • Pfizer, Inc.
  • F.Hoffmann-La Roche Ltd
  • Cibus, Ltd.
  • New England Biolabs,Inc.
  • Trofacgen,Inc.
  • GenScript, Corporation
  • GlaxoSmithKline plc.
  • Novo Nordisk A\S
  • Monsanto Company
  • Eli Lily and Company
  • Horizon Discovery Group PLC
  • Amgen Inc.
  • Novartis AG

Recent News:

  • In March 2022, PreHevbrio (recombinant hepatitis B vaccine) was introduced by VBI Vaccines Inc. in the United States to prevent infection caused by all known hepatitis B virus (HBV) subtypes in individuals 18 years of age and older. 
  • In February 2022, VBI Vaccines Inc. received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use for its trivalent hepatitis B (HBV) vaccine, PreHevbri, to induce active immunization against infection caused by all known hepatitis B virus (HBV) subtypes in adults.